<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542379841476">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">16.11.2018 14:50:41 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.1vi3rzc5m0tm8</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>I&apos;ve been made redundant &lt;a href=&quot;https://www.ecorporationbd.com/stmap_aaa80.html?cloxacillin.cialis.diskus.mobic&quot;&gt;esomeprazole webmd&lt;/a&gt;  Dr. Pamela Cyrus, VP and head of U.S. Medical Affairs for Bayer HealthCare&amp;#39;s pharma division, hailed the chance for priority review. &quot;This is an important milestone for sorafenib and the designation highlights the urgent need for new treatments for patients with this type of thyroid cancer who have limited or no treatment options,&quot; Cyrus said in a statement.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
